COVID-19's impact on bioanalytical labs
- PMID: 34374298
- PMCID: PMC8438945
- DOI: 10.4155/bio-2021-0103
COVID-19's impact on bioanalytical labs
Abstract
Tweetable abstract One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.
Keywords: COVID-19; NAAT; SARS-CoV-2 antigen; bioanalysis; clinical trials; serology.
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
References
-
- Globaldata PLC. Coronavirus disease 2019 pharma executive briefing. 59 (2021). https://pharma.globaldata.com/Analysis/TableOfContents/Coronavirus-Disea...
-
- US FDA. In Vitro Diagnostics EUAs – molecular diagnostic tests for SARS-CoV-2. http://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-eme...
-
- US FDA. In Vitro Diagnostics EUAs – serology and other adaptive immune response tests for SARS-CoV-2. http://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-eme...
-
- US FDA. COVID-19: developing drugs and biological products for treatment or prevention. FDA Guid. Ind. (2021). https://www.fda.gov/regulatory-information/search-fda-guidance-documents...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous